<DOC>
	<DOCNO>NCT01681381</DOCNO>
	<brief_summary>This prospective , multi-center , open label , randomize study evaluate efficacy safety The TIVOLI Biodegradable polymer Rapamycin-Eluting Stent compare The FIREBIRD2™ Rapamycin-eluting Stent ( DES ) Treatment Coronary Revascularization .</brief_summary>
	<brief_title>Evaluate Safety And Effectiveness Of The Tivoli® DES The Firebird2® DES For Treatment Coronary Revascularization</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>• The patient must ≥18 age ; Symptomatic ischemic heart disease and/or objective evidence myocardial ischemia include chronic stable coronary artery disease , acute coronary syndrome include nonSTelevation STelevation myocardial infarction ; Acceptable candidate CABG ; The patient willing comply specify followup evaluation ; 4.Patients agree accept followup visit . Patients understand study objective psychologically linguistically show sufficient compliance study protocol . Patients present acceptance risk benefit describe informed consent form . Angiographic Inclusion criterion : At least one lesion diameter stenosis &gt; 70 % suitable coronary stent implantation vessel reference diameter range 2.5 mm 4.0 mm ; Patients multilesion multivessel coronary disease , must successful treatment ( &lt; 30 % diameter stenosis visual estimate ) first treat lesion prior treatment lesion brand stent . Staged ( plan ) procedure must perform within 30 day index procedure . General Exclusion Criteria Pregnant nursing patient plan pregnancy period 1 year follow index procedure . Patient history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulant therapy contraindicate patient able comply dual antiplatelet therapy least 1 year ; Patient medical illness ( e.g. , cancer , know malignancy , congestive heart failure , organ transplant recipient candidate ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance protocol , confound data interpretation associate limited life expectancy ( i.e. , less 1 year ) ; Left ventricular function &lt; 40 % ; Cardiogenic shock hemodynamic compromise require pressor and/or inotropes mechanical support ; Patient know hypersensitivity contraindication aspirin , heparin , clopidogrel/ticlopidine , stainless steel alloy , cobalt chromium , Rapamycinry , styrenebutylenesstyrene polylactic acid ( PLA ) polymer , and/or contrast sensitivity adequately premedicated ; Any significant medical condition Investigator 's opinion may interfere patient 's optimal participation study ; Currently participate another investigational drug device study patient inclusion another investigational drug device study followup . Existing impairment liver kidney . Extremely tortuous and/or calcification lesion . Angiographic exclusion criterion : • Two chronic total occlusion proximal half epicardial coronary artery recannalized .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>